AVEO Oncology AVEO and Astellas Pharma Inc. (TSE: 4503) today
announced new data from the Phase 3 TIVO-1 trial (TIvozanib
Versus sOrafenib
in 1st line advanced RCC)
demonstrating the safety and tolerability profile of tivozanib versus
sorafenib in the first line setting for patients with metastatic renal
cell carcinoma (RCC). Results presented at the ESMO 2012 Congress
(European Society for Medical Oncology) in Vienna, Austria show that
patients treated with tivozanib experienced fewer Grade 3 and off-target
adverse events (AEs), stayed on treatment longer, and required fewer
dose reductions and interruptions compared with those treated with
sorafenib.1 Also presented were the first tivozanib biomarker
data in RCC, and the design of the TAURUS
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in